

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Highly Specialised Technology Evaluation (HST)

GSK2696273 for treating severe combined immunodeficiency caused by adenosine deaminase deficiency [ID926]

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • GlaxoSmithKline (GSK2696273) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Sick Children • Anthony Nolan • Climb (Children Living with Inherited Metabolic Diseases) • Genetic Alliance UK • Genetic Disorders UK • Jnetics • Muslim Council of Britain • National Children's Bureau • Primary Immunodeficiency UK • Purine Metabolic Patients' Association • South Asian Health Foundation • Specialised Healthcare Alliance • Together for Short Lives • UK Primary Immunodeficiency Network <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Genetic Nurses & Counsellors • Association of Paediatric Emergency Medicine • British Inherited Metabolic Disease Group • British Society for Gene and Cell therapy • British Society for Genetic Medicine • British Society for Human Genetics • British Transplantation Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British Society of Blood and Marrow Transplantation • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Blood and Transplant • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • United Kingdom National Screening Committee • Welsh Blood Service • Welsh Government <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Sigma-Tau Pharmaceuticals (pegylated adenosine deaminase enzyme) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Catapult Cell Therapy • Gene and Cell Therapy Group - UCL • Medical Research Council - Human Genetics Unit • MRC Clinical Trials Unit • National Institute for Health Research

Consultees	Commentators (no right to submit or appeal)
<p>Health</p> <ul style="list-style-type: none"> • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for the Study of Inborn Errors of Metabolism • Together for Short Lives • UK Clinical Pharmacy Association • UK Genetic Testing Network • Genomics England <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • Great Ormond Street Hospital – Immunology Department • Newcastle upon Tyne Hospitals NHS Foundation Trust • NHS England • NHS Wakefield CCG • NHS Luton CCG 	<p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Evaluation Determination (FED).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Evaluation Determination (FED).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FED for information only, without right of appeal. These organisations are: companies that market comparator technologies;

Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts

¹Non-company consultees are invited to submit statements relevant to the group they are representing.